NCT04356118 is a Phase 4 clinical trial of Recombinant Human Endostatin in Leptomeningeal Metastasis, sponsored by Hui Bu.

Who is sponsoring NCT04356118?

NCT04356118 is sponsored by Hui Bu.

What drugs are being tested in NCT04356118?

Interventions in NCT04356118: Recombinant Human Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer.

What condition does NCT04356118 study?

NCT04356118 studies Leptomeningeal Metastasis.

Is NCT04356118 still recruiting?

NCT04356118 is currently status unknown. Last updated 23 May 2020.

Last reviewed 2020-05-23 · How we verify

NCT04356118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Status unknown Phase 4 Last updated 23 May 2020

What this trial tests

Phase 4 trial testing Recombinant Human Endostatin in Leptomeningeal Metastasis in 30 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	Hui Bu
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2020
Primary completion	1 June 2023
Estimated completion	1 June 2023

Drugs / interventions tested

Recombinant Human Endostatin — full drug profile →
intrathcal methotrexate — full drug profile →
Targeted drugs for non-small cell lung cancer — full drug profile →

Conditions studied

Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →

Sponsor

Hui Bu — full company profile →

Who can join

18 and older, any sex, with Leptomeningeal Metastasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Leptomeningeal Metastasis Overall survival
Time frame: 36 months
Leptomeningeal Metastasis Overall survival defined as time from LM diagnosis to death due to any cause or last follow-up
Neurological Progression Free Survival
Time frame: 36 months
From the start of treatment until central nervous system metastase progression or death due to any cause
The incidence of adverse reactions
Time frame: 36 months
From date of first dose up to assessed from April 2020 to April 2023 (In accordance with the standard of CTCAE)

Sponsor's own description

The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.
Pellerino A, Brastianos PK, Rudà R, Soffietti R. · · 2021 · cited 32× · PMID 34207653 · DOI 10.3390/cancers13122888
Leptomeningeal Metastases: New Opportunities in the Modern Era.
Wilcox JA, Li MJ, Boire AA. · · 2022 · cited 25× · PMID 35790709 · DOI 10.1007/s13311-022-01261-4
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, et al · · 2023 · cited 8× · PMID 37232842 · DOI 10.3390/curroncol30050384

Verify or expand the search:

Other trials of Recombinant Human Endostatin

Trials testing the same drug.

NCT03925233 — Breast Cancer Treatment Based on Organ-like Culture · unknown

Other recruiting trials for Leptomeningeal Metastasis

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting
NCT07098806 — Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases · Phase 1 · recruiting
NCT06984523 — Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomening · NA · active not recruiting

Other Hui Bu trials

Trials by the same sponsor.

NCT04833205 — Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lu · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04356118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hui Bu
Last refreshed: 23 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04356118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing